Head-to-head · WeighScore
Lttl vs Semaglutide Online
The verdict
Semaglutide Online takes it — 74.3/100 to 66.1/100.
Semaglutide Online grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Semaglutide Online is a LegitScript-certified telehealth platform prescribing compounded and brand-name GLP-1/GIP medications nationwide (excluding Alabama).
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Lttl | Semaglutide Online |
|---|---|---|
| WeighScore | 66.1/100 | 74.3/100 |
| Grade | C | C |
| Scorecard rank | #204 | #64 |
| Semaglutide | $199/mo (all doses, compounded) | $199/mo (all doses, compounded) |
| Tirzepatide | $279/mo (all doses, compounded) | $299/mo (all doses, compounded) |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Yes |
Graded #204 · C
Strengths
- Publishes the full price matrix — every medication, form and commitment length — on a public /plans page before checkout
- Flat dose pricing: 'Same price at every dose,' so moving to a higher dose does not raise the monthly bill
- States plainly that its compounded GLP-1s 'are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality'
- Microdose line prices low-dose semaglutide or tirzepatide at $149/mo month-to-month for people sensitive to side effects
- Oral ODT semaglutide offered for members who want to avoid injections
Where it loses points
- Partner pharmacies are never named — the site refers only to 'a partner U.S. pharmacy' (a material disclosure gap for a YMYL purchase)
- The advertised 'Plans start at $129/mo' is the 12-month prepay rate; true month-to-month is $199 semaglutide and $279 tirzepatide
- No public list of states served — eligibility depends on where unnamed 'partner providers are licensed'
- Site banner promises 'Prescribed and shipped within 48 hours' while the shipping policy states 2-5 business days to process plus 3-7 to deliver
- Medications cannot be returned or refunded once they ship from the pharmacy
Graded #64 · C
Strengths
- LegitScript certified — passes accreditation standards recognized by Google and Visa for online telehealth
- Compounded all-in pricing: semaglutide $199/mo and tirzepatide $299/mo includes medication, provider care, and shipping
- Brand-name options (Wegovy pill, injectable sema, Zepbound) available for eligible patients, potentially $0-$25/mo with insurance
- Nationwide (49 states + DC); no appointment required, licensed provider reviews intake within 12 hours
- 0% financing through Credee from $79/month (12-24 months) plus Affirm and Klarna with ~97% approval rate
Where it loses points
- No labs or clinical monitoring disclosed — blood work requirements not mentioned anywhere on site
- Leadership team and medical director not identified on site — no named prescribers or company founders published
- Brand-name prescriptions add a $44/month provider fee on top of medication cost, raising total price to $193-$343/mo
- No coaching, dietitian, or behavioral support at any tier — medication and async provider access only
- 30-day satisfaction guarantee covers evaluation fee only; medication costs explicitly non-refundable
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.